Godavari Drugs Ltd vs Raymed Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 126.1 as of 07 May 15:30 . The P/E Ratio of Godavari Drugs Ltd changed from 8.4 on March 2021 to 15 on March 2025 . This represents a CAGR of 12.30% over 5 yearsThe P/E Ratio of Symed Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Godavari Drugs Ltd changed from ₹ 34.45 crore on March 2021 to ₹ 65.86 crore on March 2025 . This represents a CAGR of 13.84% over 5 yearsThe Market Cap of Symed Labs Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Godavari Drugs Ltd for the Dec '25 is ₹ 22.45 crore as compare to the Sep '25 revenue of ₹ 27.28 crore. This represent the decline of -17.71% The revenue of Symed Labs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Godavari Drugs Ltd for the Dec '25 is ₹ 2.75 crore as compare to the Sep '25 ebitda of ₹ 2.63 crore. This represent the growth of 4.56% The ebitda of Symed Labs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Godavari Drugs Ltd changed from ₹ 1.63 crore to ₹ 0.76 crore over 6 quarters. This represents a CAGR of -39.87% The net profit of Symed Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of 0.0% The Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Symed Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates and fine chemicals catering to global life science industry.
It works a manufacturing plant at Nanded, Maharashtra, India.
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand.
Company apart from its own products, explores continual opportunities for loan licence manufacturing with reputed multinational companies. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.

FAQs for the comparison of Godavari Drugs Ltd and null

Which company has a larger market capitalization, Godavari Drugs Ltd or Symed Labs Ltd?

Market cap of Godavari Drugs Ltd is 127 Cr while Market cap of Symed Labs Ltd is 0 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Symed Labs Ltd?

The stock performance of Godavari Drugs Ltd and Symed Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Symed Labs Ltd?

As of May 7, 2026, the Godavari Drugs Ltd stock price is INR ₹126.1. On the other hand, Symed Labs Ltd stock price is INR ₹0.0.

How do dividend payouts of Godavari Drugs Ltd and Symed Labs Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Symed Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.